At the time of writing, Amneal Pharmaceuticals Inc [AMRX] stock is trading at $12.91, down -0.31%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AMRX shares have gain 2.70% over the last week, with a monthly amount glided 3.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amneal Pharmaceuticals Inc [NASDAQ: AMRX] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $15. Previously, Goldman started tracking the stock with Buy rating on June 06, 2025, and set its price target to $12. On February 24, 2025, upgrade upgraded it’s rating to Overweight and revised its price target to $12 on the stock. JP Morgan upgraded its rating to a Neutral but stick to its price target of $9 on September 06, 2024. Goldman upgraded its rating to Buy for this stock on March 08, 2021, and upped its price target to $6.50. In a note dated December 14, 2020, Guggenheim upgraded a Buy rating on this stock but restated the target price of $5.50.
For the past year, the stock price of Amneal Pharmaceuticals Inc fluctuated between $6.68 and $13.01. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Amneal Pharmaceuticals Inc [NASDAQ: AMRX] shares were valued at $12.91 at the most recent close of the market. An investor can expect a potential return of 16.19% based on the average AMRX price forecast.
Analyzing the AMRX fundamentals
According to Amneal Pharmaceuticals Inc [NASDAQ:AMRX], the company’s sales were 2.93B for trailing twelve months, which represents an 11.68% jump. Gross Profit Margin for this corporation currently stands at 0.37% with Operating Profit Margin at 0.1%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.05 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.82 points at the first support level, and at 12.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.99, and for the 2nd resistance point, it is at 13.07.
Ratios To Look Out For
It is important to note that Amneal Pharmaceuticals Inc [NASDAQ:AMRX] has a current ratio of 2.13. As well, the Quick Ratio is 1.42, while the Cash Ratio is 0.23. Considering the valuation of this stock, the price to sales ratio is 1.38 and price to earnings (TTM) ratio is 909.15.
Transactions by insiders
Recent insider trading involved Nark Ted C, Director, that happened on Nov 17 ’25 when 50000.0 shares were sold. Director, Nark Ted C completed a deal on Nov 17 ’25 to buy 50000.0 shares. Meanwhile, Executive Vice President Shah Nikita sold 0.13 million shares on Nov 12 ’25.
